StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Down 12.8 %
NASDAQ:EVOK opened at $0.48 on Thursday. Evoke Pharma has a 52 week low of $0.42 and a 52 week high of $2.42. The firm’s 50-day simple moving average is $0.62 and its 200 day simple moving average is $0.93.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The business had revenue of $1.68 million for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- The How and Why of Investing in Biotech Stocks
- Comprehensive PepsiCo Stock Analysis
- Manufacturing Stocks Investing
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
